New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.» Read More
German pharmaceutical group Merck is seeking a partnership with an Iranian manufacturer to produce medicines. The FT reports.
Dec 24- Actavis Plc said U.S. health regulators denied approval to its contraceptive patch for women and asked for more data. The generic drugs maker, which received a "complete response letter" from the FDA, said it planned to work closely with the agency to address the questions.
Dec 23- Tesaro Inc's experimental drug for treating chemotherapy-induced nausea and vomiting failed to show enough benefit in trials to give it an edge over competing drugs, sending its shares down as much as 24 percent.
Merck issued a voluntary recall of lot of its Gardasil vaccines Friday due to the risk that some of the viles may contain glass particles.
Sometimes going separate ways is better for everyone involved. Everyone.
The breach came to light last month when the FDA sent letters to users of an online system at the Center for Biologics Evaluation and Research. The letters said the breach was detected by the FDA on Oct. 15 and that it resulted in the theft of usernames, phone numbers, email addresses and passwords.
LONDON, Dec 16- A new battle is looming over access to antiviral medicines in developing countries- this time for treating hepatitis C- more than a decade after a global showdown over the price of AIDS drugs in Africa.
*AstraZeneca shares gain 2.2 percent. Dec 13- A new type of diabetes drug from Bristol-Myers Squibb and AstraZeneca has been endorsed by U.S. medical experts, two years after it was rejected by regulators because of safety concerns.
Bristol-Myers Squibb is developing the drug, which is already approved in Europe, in partnership with AstraZeneca. The FDA typically follows the advice of its advisory panels, but is under no obligation to do so.
Bristol-Myers is developing the drug, which is already approved in Europe, in partnership with AstraZeneca Plc. The FDA typically follows the advice of its advisory panels, but is under no obligation to do so.
Dec 12- A panel of experts advising the U.S. Food and Drug Administration said an oral drug made by Merck& Co was effective in treating grass pollen allergy but expressed concerns about the drug's safety in children. It is sold as Grazax in Europe by Merck's partner ALK Abello.
Dec 11- An oral immunotherapy drug for treating grass pollen allergies was backed by an independent advisory panel to the U.S. Food and Drug Administration on Wednesday.
"Because antimicrobial drug use in both humans and animals can contribute to the development of antimicrobial resistance, it is important to use these drugs only when medically necessary," the FDA said in a release.
LONDON, Dec 11- Leading countries set a goal of finding a cure or effective treatment for dementia by 2025 on Wednesday and ministers said the world needed to fight the spread of the memory-robbing condition just as it fought AIDS.
LONDON, Dec 11- The world needs to fight the spread of dementia in the same way it mobilised against AIDS, a British government minister told a special summit on the disease on Wednesday, saying failure to tackle it would wreck state health budgets.
Next year is an election year. There is little chance of a big tax increase, or a government shutdown or debt crisis.
Dec 10- AbbVie Inc's all-oral hepatitis C therapy cured 96 percent of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, keeping the company well placed in a highly competitive race to deliver new treatments for the serious liver disease.
Dec 10- Merck& Co said on Tuesday it will advance its experimental Alzheimer's drug into late-stage trials among patients with mild to moderate disease, after an independent monitoring board reviewed its safety and recommended the trial continue to recruit patients.
Dec 10- Merck& Co said it will advance its experimental Alzheimer's drug into late-stage trials among patients with mild to moderate disease, after an independent monitoring board reviewed its safety and recommended the trial continue to recruit patients.
NEW YORK, Dec 9- Merck& Co Inc said on Monday that it was prepared to pay $27.7 million to settle lawsuits by hundreds of people who sued the company over allegations that its osteoporosis drug Fosamax caused bones in the jaw to deteriorate.